Sarepta Therapeutics Inc (NASDAQ:SRPT) shares sank in Thursday’s trading session after the FDA released negative briefing documents regarding the company’s Duchenne muscular dystrophy …
Needham analyst Chad Messer came out with commentary on ISIS Pharmaceuticals, Inc. (NASDAQ:ISIS) following recent updates from two ongoing Phase II studies with ISIS-SMNRx, a drug to …
